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Second, could these markers actually be reﬂecting
glomerular inﬂammation? Severe interstitial inﬂammation is
more commonly associated with class III or IV.2 Even in this
study, 11/12 (92%) class II and class V biopsies, 11/15 (73%)
class III (or IIIþV) biopsies, and 25/37 (68%) class IV
biopsies had none–mild interstitial inﬂammation. Thus, there
is a need to adjust for severity of glomerular disease. It will be
interesting to know the performance of these biomarkers
looking at class III and class IV only, and with regard to the
activity index (sans interstitial inﬂammation). Only then
perhaps can we be sure that they truly represent interstitial
inﬂammation.
Third, they have talked about biomarkers being used
‘following therapy of lupus nephritis’ and to ‘individualize
treatment decisions’. Indeed, a biomarker of interstitial
inﬂammation (and ﬁbrosis) may have prognostic signiﬁ-
cance.2 However, therapy and indeed our classiﬁcation
systems continue to focus on glomerular inﬂammation.3,4
Thus, unless interstitial inﬂammation itself is incorporated
into classiﬁcation and becomes a guide to therapy, it is
unlikely that a biomarker of the same will help make treat-
ment decisions.
1. Zhang X, Nagaraja HN, Nadasdy T et al. A composite urine biomarker
reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney
Int 2012; 81: 401–406.
2. Hsieh C, Chang A, Brandt D et al. Predicting outcomes of lupus nephritis
with tubulointerstitial inflammation and scarring. Arthritis Care Res
(Hoboken) 2011; 63: 865–874.
3. McCluskey RT. Lupus nephritis. In: Sommers SC (ed). Kidney Pathology
Decennial 1966–1975. Appleton-Century-Crofts: East Norwalk, CT, 1975,
pp 435–450.
4. Weening JJ, D’Agati VD, Schwartz MM et al. The classification of
glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc
Nephrol 2004; 15: 241–250.
Varun Dhir1
1Department of Internal Medicine, Rheumatology Unit, Post Graduate
Institute of Medical Education and Research, Chandigarh, India
Correspondence: Varun Dhir, Department of Internal Medicine,
Rheumatology Unit, Post Graduate Institute of Medical Education and
Research, Chandigarh, India. E-mail: varundhir@gmail.com
Kidney International (2012) 82, 243–244; doi:10.1038/ki.2012.98
The Authors Reply: Dr Dhir1 raises several interesting
points concerning our recent publication on biomarkers of
tubulointerstitial injury in lupus nephritis (LN)2 that support
the potential clinical utility of these biomarker equations.
Our responses in order are as follows: (1) The biomarker
equations are intended to provide a readout of kidney
pathology continuously in real time to follow the response of
the tubulointerstitium to therapy. (2) To examine speciﬁcity
of the biomarker equations for the tubulointerstitium as
opposed to the glomeruli, we tested the ability of the inﬂam-
mation equation (equation 1) to determine the presence or
absence of glomerular endocapillary proliferation (39% mis-
classiﬁed) and the presence of crescents/necrosis in410% of
glomeruli (33% misclassiﬁed). The ﬁbrosis equation (equation
2) was used to identify biopsies having glomerulosclerosis in
425% of glomeruli (28% misclassiﬁed). These results are
not unexpected, because although lesions in the glomerular
and interstitial compartments are correlated, the correlations
are weak to moderate.3 However, the biomarkers used to
derive equations 1 and 2 appear to also be relevant for
glomerular pathologies, but will require different optimization
of weighting and cutoffs. Such optimization can readily
be accomplished using discriminant analysis, illustrating
the applicability of this technique for biomarker develop-
ment in LN and other kidney diseases. (3) Despite current
glomerulocentric classiﬁcations of LN, it is well recognized
that chronic tubulointerstitial damage determines long-term
renal prognosis,4 and therapeutic targeting of tubulointer-
stitial injury does not necessarily need to wait until
classiﬁcation schemes better acknowledge the importance of
the tubulointerstitium.
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Laparoscopic approach for the
evaluation of peritoneal injury
To the Editor: Encapsulating peritoneal sclerosis (EPS) is a
severe complication of long-term peritoneal dialysis (PD)
with a high mortality rate. EPS is characterized by a progres-
sive inﬂammatory process resulting in the development of
intra-abdominal ﬁbrosis that envelops and constricts the
viscera, thereby compromising the motility and function of
the intestine, leading to partial and complete intestinal
obstruction.
Takara and Ishibashi1 reported that an endoscopy could be
used for the treatment for obstructed peritoneal catheter. Here
we used an endoscope for the diagnosis of EPS. We used a
laparoscopic approach for the evaluation of peritoneal injury
in PD patients. The peritoneum of a 64-year-old woman who
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